Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02456831 · ClinicalTrials.gov registry record · NA
Soy Formula Feedings in Healthy, Term Infants
A NA study of Gastrointestinal Tolerance, sponsored by Abbott Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 115
- Enrollment target
- 7
- Study locations
NCT02456831: Completed NA study of Gastrointestinal Tolerance, sponsored by Abbott Nutrition.
NCT02456831 is a NA study of Gastrointestinal Tolerance that has completed, run by Abbott Nutrition. The registered enrollment target is 115 participants, below the 179-participant average among 4 other Gastrointestinal Tolerance trials with a reported enrollment target (36% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02456831, a NA study of Gastrointestinal Tolerance, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 115 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study evaluates the GI tolerance and acceptability of soy formulas fed to healthy term infants with reported intolerance to a milk-based formula.
Primary Outcome
stool number, consistency, and color
Conditions Studied
Interventions
- OTHER Experimental Infant Formula 1
- OTHER Experimental Infant Formula 2
- OTHER Experimental Infant Formula 3
- OTHER Active Comparator: Control Infant Formula
Study Locations (7)
Arkansas
- Arkansas Children's Hospital - Little Rock
Illinois
- Dreyer Clinic - Aurora
Kentucky
- T&W Research - Owensboro
Minnesota
- Park Nicollet Medical Foundation - Minneapolis
Ohio
- Clinical Studies, Inc - Canton
Tennessee
- Research Memphis - Memphis
Texas
- Child Care Associates - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 1992-12 |
| Est. Completion | 1994-06 |
| Phase | NA |
What the finished NCT02456831 record still lists
NCT02456831 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 179-participant average among 4 other Gastrointestinal Tolerance trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Gastrointestinal Tolerance appearing as the primary indexed condition, and to 4 interventions - of which Experimental Infant Formula 1 is the first listed.
NCT02456831 lists 7 locations in 7 states (Arkansas, Illinois, Kentucky).
Frequently Asked Questions
What is clinical trial NCT02456831 about?
NCT02456831 is a clinical study titled "Soy Formula Feedings in Healthy, Term Infants". This study evaluates the GI tolerance and acceptability of soy formulas fed to healthy term infants with reported intolerance to a milk-based formula.
What is the current status of trial NCT02456831?
This trial is currently completed. It is a NA study. The enrollment target is 115 participants. The study started on 1992-12. Estimated completion is 1994-06.
What conditions does trial NCT02456831 study?
This clinical trial studies the following conditions: Gastrointestinal Tolerance.
What interventions are being tested in trial NCT02456831?
The interventions under investigation include: Experimental Infant Formula 1 (OTHER), Experimental Infant Formula 2 (OTHER), Experimental Infant Formula 3 (OTHER), Active Comparator: Control Infant Formula (OTHER).
Who is sponsoring clinical trial NCT02456831?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02456831 being conducted?
This trial has 7 study locations across Arkansas, Illinois, Kentucky, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Tolerance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia